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Orkambi® treatment
P. Ericson1, A. Hedborg2, I. de Monestrol2, L. Hjelte2, U. Lindberg3,
C. Hansen3, C. Krantz4, M. Gilljam1, A. Lindblad1. 1Sahlgrenska University
Hospital, Gothenburg CF Center, Gothenburg, Sweden; 2Karolinska University
Hospital, Stockholm CF Center, Stockholm, Sweden; 3Skåne University
Hospital, Lund CF Center, Lund, Sweden; 4Akademiska University Hospital,
Uppsala CF Center, Uppsala, Sweden
Objectives: Starting July 1, 2018, the Dental and Pharmaceutical Benefits
Agency decided that Orkambi® was to be subsidized by the Swedish state.
The decision was accompanied by the following restrictions: 1. Treatment
initiated at a CF Centre with close follow-up of effect and adverse events
2. Set treatment goals evaluated after one year 3. Follow-up via the Swedish
CF Registry.
The aim was to investigate whether the registry could facilitate the
evaluation of Orkambi® treatment.
Methods: A national follow-up program for the first year of Orkambi®
treatment was established by The Swedish CF Working Group. Extra fields
were added to the registry to fit the program and staff was hired to ensure
that data was entered correctly. Mandatory check-ups were at treatment
start and after 1, 3, 6, 9 and 12 months.
Results: The registry is used by all 4 centres and all patients that initiated
Orkambi® are included in the follow-up program. Up to July 31, 2019, 190
patients entered the program. 25 (13%) patients stopped treatment due to
adverse events. Mean age (SD) at start was 22.9 (12.7) yrs with FEV1pp of
77 (22)% and LCI (< 18 yrs) 8.89 (1.99). BMI in adultswas 21.9 (2.51) and BMI
z-score in children −0.35 (0.82).
87 patients (35 children) had been on treatment for >6 months July 31,
2019. The sweat test decreased in average 18 mmol/l (range −48 to
+14 mmol/l) after 3 months. After 6 months, FEV1 showed a trend of
improvement in the adult population while it was stable in the paediatric
population (6–18 yrs) where a decrease of LCI (0.7 units) was seen. Both
BMI and BMI z-score showed a slight increase. Comparing the 180 days
before starting Orkambi® to the180 days after treatment start, the mean
number of days on iv antibiotics per patient decreased from 7.2 to 3.1 days.
Conclusions: The follow-up program for Orkambi® shows that the Swedish
CF-registry is a useful tool for evaluation of new therapies. Longer follow-
up time will be presented in June 2020.
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Tobacco smoke exposure limits the benefit of Symdeko® in paediatric
cystic fibrosis patients: Cystic Fibrosis Foundation Patient Registry
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Objectives: Tobacco smoke exposure reduces CFTR functional expression in
vitro and contributes to acquired CFTR dysfunction in animal models. We
investigated whether smoke exposure inhibits the clinical benefit of CFTR
modulators, focusing on tezacaftor/ivacaftor (SYMDEKO®), FDA-approved
in February 2018 for F508del homozygous patients age 12 years and older.
Methods: A retrospective analysis of data in the CF Foundation Patient
Registry (CFFPR, 2016–2018) compared change in lung function (GLI
FEV1%) after SYMDEKO
® initiation in smoke-exposed vs unexposed
patients age 12–18 years. Smoke exposure was dichotomized based on
annual self-report. Its impact was assessed with fixed-effects modelling,
which accounts for non-time-varying factors (sex, race, parent education)
and additionally controlled for time-varying covariates.
Results: SYMDEKO® was prescribed to 1,429 patients: mean age 14.7 (SD
0.07) years, 54.6% female, mean baseline FEV1% 83.3 (0.51), 27.6% smoke-
exposed. During the study period, FEV1% improved 0.25% (95% CI: −0.39,
0.89) in those on SYMDEKO® and declined −2.4% (−2.80, −2.05) in those
not on the drug. Among those on SYMDEKO®, FEV1% improvement varied
by smoke exposure (p < 0.001). In unexposed subjects, FEV1% increased
0.72% (0.03, 1.41), while in smoke-exposed it declined 1.03% (−2.5, 0.5). In
fixed-effect models, FEV1% improvement remained significant in unex-
posed subjects (0.5%; 0.08, 0.9, p = 0.017), while in smoke-exposed subjects
there was no improvement (−0.44%; −0.20, 0.4, p = 0.452).
Conclusion: Smoke exposure blunts the therapeutic effect of tezacaftor/
ivacaftor in CF patients ages 12–18 years. Future analysis will assess the
consequence of smoke exposure in the recently FDA-approved triple-
combination agent (elexacaftor/tezacaftor/ivacaftor, Trikafta®). Although
findings need to be validated with biomarkers of smoke exposure and in
other cohorts, these data suggest that limiting smoke exposure may help
enhance the benefit of CFTR modulators.
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Studied Cystic Fibrosis (CF) modulators have been announced to cover 90%
of all CF patients. A genotype-agnostic novel therapy for CF is under
development, which will focus on peoplewith CF who havemutations that
are not eligible for the approved small molecule modulators and triple
combination therapies. The data in the European Cystic Fibrosis Society
Patient Registry (ECFSPR) are used to provide a quantitative overview of
eligible patients.
Patients who are alive and seen during the 2017, or alive and not seenwere
considered (excluding France who delivered the data directly to the
sponsor). Not considered were patients F508del homozygotes eligible for
elexacaftor/tezacaftor/ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor,
or heterozygotes eligible for elexacaftor/tezacaftor/ivacaftor. Neither were
patients with at least one of the following mutations: E56 K, P67L, R74W,
D110E, D110H, R117C, E193 K, L206W, R347H, R352Q, A455E, D579G, 711
+3A->G, E831X, S945L, S977F, F1052 V, K1060 T, A1067 T, R1070W, F1074L,
D1152H, D1270N, 2789+5G->A, 3272-26A->G, 3849+10kbC->T (eligible for
tezacaftor/ivacaftor, ivacaftor) and R117H, G178R, S549N, S549R, G551D,
G551S, G1069R, R1070Q, G1244E, S1251N, S1255P, G1349D (eligible for
ivacaftor).
From the 41,264 patients registered in the ECFSPR for the 2017, 4,798
patients (12%) carrya genotype that is not eligible to the currentlyapproved
modulators or the triple combo. The percentage of non-eligible patients
varies from 2,3% in Ireland to 71,9% in Armenia. 2,954 of these patients are
11 years or older, 1,561 have a FEV1% of predicted value between 40% and
90%.
In Europe approximately 88% of the patients will be eligible for the
currently approved modulators or triple combo, in some countries this
percentage is below 50%. With the ECFSPR data, a realistic and useful
overview could be created to support the design of a study for patients that
are not eligible to the currently available modulator and triple combination
therapies.
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Objectives: Improved outcomes and survival for people with CF is owed
largely to the success of therapeutic innovation and treatments available to
manage symptoms. However, there is anecdotal evidence that access to key
treatments varies greatly across countries and settings.
We aim to conduct a novel Europe-wide survey to describe variation in
perceived access to medications for people with CF. This pilot survey stage
aims to assess the acceptability and feasibility of a pan-European survey,
ensure questionnaire items identify variability between and within
countries, and generate a valid questionnaire that provides patient- and
clinician-led perspectives on access to treatments.
Methods: The online pilot survey will be administered via SurveyMonkey
to respondents from 6 CF Europe member countries - Belgium, France,
Israel, Slovakia, UK and Poland.
Survey responses will be subjected to descriptive analysis, with primary
focus on assessing feedback onwording and structure of the questionnaire.
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